Metabolically healthy versus metabolically unhealthy obesity.

Adipogenesis Adiposopathy Cardiovascular disease Gut microbiota Metabolically healthy and unhealthy obesity Type 2 diabetes

Journal

Metabolism: clinical and experimental
ISSN: 1532-8600
Titre abrégé: Metabolism
Pays: United States
ID NLM: 0375267

Informations de publication

Date de publication:
03 2019
Historique:
received: 25 08 2018
revised: 10 11 2018
accepted: 15 11 2018
pubmed: 21 11 2018
medline: 26 11 2019
entrez: 21 11 2018
Statut: ppublish

Résumé

Obesity-related disease complications reduce life quality and expectancy and increase health-care costs. Some studies have suggested that obesity not always entails metabolic abnormalities and increased risk of cardiometabolic complications. Because of the lack of universally accepted criteria to identify metabolically healthy obesity (MHO), its prevalence varies widely among studies. Moreover, the prognostic value of MHO is hotly debated, mainly because it likely shifts gradually towards metabolically unhealthy obesity (MUO). In this review, we outline the differential factors contributing to the metabolic heterogeneity of obesity by discussing the behavioral, genetic, phenotypical, and biological aspects associated with each of the two metabolic phenotypes (MHO and MUO) of obesity and their clinical implications. Particular emphasis will be laid on the role of adipose tissue biology and function, including genetic determinants of body fat distribution, depot-specific fat metabolism, adipose tissue plasticity and, particularly, adipogenesis. Finally, the emerging role of gut microbiota in obesity and adipose tissue dysfunction as well as the search for novel biomarkers for the obesity-related metabolic traits and associated diseases will be briefly presented. A better understanding of the main determinants of a healthy metabolic status in obesity would allow promotion of this favorable condition by targeting the relevant pathways.

Identifiants

pubmed: 30458177
pii: S0026-0495(18)30248-8
doi: 10.1016/j.metabol.2018.11.009
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

51-60

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Carla Iacobini (C)

Department of Clinical and Molecular Medicine, "La Sapienza" University, Rome, Italy.

Giuseppe Pugliese (G)

Department of Clinical and Molecular Medicine, "La Sapienza" University, Rome, Italy.

Claudia Blasetti Fantauzzi (C)

Department of Clinical and Molecular Medicine, "La Sapienza" University, Rome, Italy.

Massimo Federici (M)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Stefano Menini (S)

Department of Clinical and Molecular Medicine, "La Sapienza" University, Rome, Italy. Electronic address: stefano.menini@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH